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Objective: To retrospectively investigate cesarean scar pregnancy (CSP) patients who received systemic
methotrexate (MTX) and to clarify the criteria for administering systemic MTX to CSP patients.
Materials and methods: Fifteen CSP patients who were initially treated with systemic MTX (50 mg/m2/
week) were included. Nine patients, who needed a uterine artery embolization (UAE) or a laparotomy,
including a transabdominal hysterectomy (TAH), were defined as the unsuccessful MTX group. Six pa-
tients who did not require UAE or a laparotomy were defined as the successful MTX group. Furthermore,
the hCG cut-off value and the GS cut-off size at the time of CSP diagnosis, which differentiated successful
and unsuccessful patients, were defined. MTX success rates were investigated by combining the hCG and
gestational sac (GS) size cut-off values.
Results: The hCG cut-off value was 17757.0 mIU/mL, and the GS cut-off size was 10.4 mm. In patients
with hCG values less than 17757.0 mIU/mL, the MTX success rate was 75.0%. Fewer patients needed UAE
or a laparotomy compared to patients with hCG values higher than 17757.0 mIU/mL (P ¼ 0.007). In
patients with a GS size less than 10.4 mm, the MTX success rate was 80.0%. Fewer patients among them
needed UAE or a laparotomy compared to those among patients with a GS size greater than
10.4 mm (P ¼ 0.089). In patients with hCG values and GS sizes lower than the cut-off values, the MTX
success rate was 80.0%. Fewer patients among them needed UAE or a laparotomy compared to those
among patients with hCG values and/or GS sizes higher than the cut-off values, respectively (P ¼ 0.010).
Conclusion: Patients with hCG values less than 17757.0 mIU/mL and GS sizes less than 10.4 mmmay have
a greater chance of successful systemic MTX treatment when it is used as the first line of treatment for
CSP.
© 2021 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In recent years, the frequency of cesarean section deliveries has
increased along with the incidence of cesarean scar pregnancies
(CSPs) [1,2]. It has been reported that CSP occurs in 0.15% of preg-
nancies, accounting for 6.1% of all ectopic pregnancies [3]. In the
management of CSP, early diagnosis and prompt treatment are vital
in the prevention of catastrophicmaternal hemorrhage. However, it
has also been reported that some CSPs can continue to full-term [4].




Gynecology. Publishing services bMany previous publications have discussed the medical
treatment of CSP patients using methotrexate (MTX) [5e13]. In a
randomized controlled trial reported by Peng et al. the thera-
peutic effects of systemic MTX and local MTX administration
were examined [5]. The completion rate of treatment was 67.3%
for the administration of systemic MTX and 69.2% for the
administration of local MTX, and both routes were deemed
effective [5]. However, as CSP can cause massive bleeding during
the course of MTX treatment, some of the patients required
uterine artery embolization (UAE) or a transabdominal hyster-
ectomy (TAH) [14]. Further studies are required in order to clarify
and enhance the effects of MTX in CSP patients. To increase the
therapeutic effect of MTX, it is necessary to examine the effec-
tiveness of systemic MTX for CSP and clarify the criteria for
administering systemic MTX for CSP.y Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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received systemic MTX for CSP across multiple perinatal medical
centers and compared CSP patients who were successfully and
unsuccessfully treated with systemic MTX. This study aimed to
clarify the criteria for administering systemic MTX for CSP.
Patients and methods
Fifteen patients who were diagnosed with CSP in early preg-
nancy and received systemic MTX (50 mg/m2 per week) as the first
treatment were included in this study. These patients were treated
in 11 perinatal medical centers between January 2006 and
December 2015. The criterion for a diagnosis of CSP included the
absence of a gestational sac (GS) in the uterine cavity or cervical
canal and the presence of a GS in the cesarean scar site in early
pregnancy. Patients who were diagnosed with CSP in the early
stages of pregnancy and received local MTX and potassium chloride
(KCl) were excluded along with patients who selected surgery as
the first treatment option. Systemic MTX was administered be-
tween one and seven times, based on the human chorionic
gonadotropin (hCG) values. Indications of repeated MTX injection
included a lack of extensive bleeding during the clinical course of
CSP and a decrease in hCG values after systemic MTX administra-
tion. If there was massive bleeding during the clinical course of CSP
and/or no decrease in hCG values after systemic MTX administra-
tion, the administration of these injections was stopped. In-
dications for UAE or laparotomy after systematic MTX
administration included extensive bleeding, an increased risk of
extensive bleeding, and/or no decrease in hCG levels. Patients who
needed UAE or a laparotomy, including TAH, were defined as the
unsuccessful systemic MTX group, and patients who did not need
UAE or laparotomy were defined as the successful systemic MTX
group. Age, number of pregnancies, number of deliveries, number
of previous cesarean sections, number of gestational weeks at the
diagnosis of CSP, hCG levels at the time of CSP, the size of the GS at
the time of CSP diagnosis, the presence of a fetal heartbeat at the
time of CSP diagnosis, and the presence of genital bleeding the time
of CSP diagnosis were retrospectively compared between the two
groups. Using a receiver operating characteristic (ROC) curve, the
hCG cut-off value at CSP diagnosis and the size of the GS at CSP
diagnosis were identified in the two groups. The patients were
divided on the basis of the hCG cut-off value and the size of the GS
at the time of CSP diagnosis. The success rates of systemic MTX
were investigated by combining the hCG cut-off value and the cut-
off size of the GS.
The ManneWhitney U test and the Fisher's test were used for
statistical analysis; P < 0.05 was considered to be significant.Table 1
Characteristics of 15 patients who chose systemic methotrexate as their first CSP treatm
treated with systemic MTX.
All patients (n ¼ 15)
Age (years)a 34.0 (27.0e44.0)
Number of pregnanciesa 2.0 (1.0e5.0)
Number of deliveriesa 2.0 (1.0e5.0)
Number of previous cesarean sectionsa 2.0 (1.0e5.0)
Gestational weeks at the diagnosis of CSP (weeks)a 6.0 (5.0e8.0)
hCG value at the diagnosis of CSP (mIU/ml)a 14491.2 (2271.0e88502.8)
GS size at the diagnosis of CSP (mm)a 13.0 (3.5e51.0)
MTX dose (mg) 150 (50e350)
Presence of fetal heartbeat 5 (33.3%)
Genital bleeding 10 (66.7%)
Blood transfusion 3 (20.3%)
Future pregnancies 5 (33.3%)
CSP, cesarean scar pregnancy; GS, gestational sac; MTX, methotrexate.
a Data are presented as medians (range).
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was used to perform the statistical analysis.
This study was conducted under the approval of the Ethics
Committees of each institution. The requirement for informed
consent was waived by the ethics committees because the infor-
mation used in this retrospective study, including the research
plans, had been previously published on the internet.
Results
The characteristics of patients who receivedmedicinal therapies
as the first treatment for CSP are shown in Table 1. At the time of
CSP diagnosis, the median number of gestational weeks was six
weeks (range, fiveeeight weeks), the median hCG value was
14491.2 mIU/mL (range, 2271.0e88502.8 mIU/mL), and the median
size of the GS was 13.0 mm (range, 3.5e51.0 mm). Of the total 15
patients, five patients (33.3%) exhibited fetal heartbeats, 10 (66.7%)
exhibited genital bleeding, and three (20.0%) received blood
transfusions during the treatment. Of the total 15 patients, five
(33.3%) were able to have future pregnancies (Table 1).
Of the 15 CSP patients who selected systemic MTX as their first
treatment, treatment was unsuccessful in nine patients (60.0%) and
successful in six patients (40.0%) (Table 1). The hCG value was
significantly higher in the unsuccessful group than in the successful
group (Table 1). There was no difference in the MTX dose between
the unsuccessful group and the successful group (Table 1).
Using an ROC curve, the hCG cut-off value and size of the GS at
CSP diagnosis were identified in the successful and unsuccessful
patients. An hCG value of 17757.0 mIU/mL (area under curve [AUC]:
0.85, sensitivity: 77.8, specificity: 100.0) and a GS size of 10.4 mm
(AUC: 0.74, sensitivity: 88.9, specificity: 66.7) were determined as
cut-off values that differentiated successful from unsuccessful
patients.
Of the eight patients with hCG values less than 17757.0 mIU/mL,
six (75.0%) did not need UAE or a laparotomy, and only two patients
(25.0%) needed UAE or a laparotomy. However, of the seven pa-
tients with hCG values of 17757.0 mIU/mL or higher, all patients
needed UAE or a laparotomy. In the groupwith hCG values less than
17757.0 mIU/mL, significantly fewer patients needed UAE or a
laparotomy compared to patients with hCG values of 17757.0 mIU/
mL or higher (P ¼ 0.007) (Fig. 1).
Among the five patients with a GS size less than 10.4 mm, four
(80.0%) did not need UAE or a laparotomy, and only one (20.0%)
needed UAE or a laparotomy. Among the 10 patients with a GS size
of 10.4 mm or larger, two (20.0%) did not need UAE or a laparotomy,
and eight (80.0%) did need UAE or a laparotomy. In the group with
GS sizes less than 10.4 mm, fewer patients needed UAE or aent and a comparison of the characteristics in successful and unsuccessful patients
Unsuccessful group (n ¼ 9) Successful group (n ¼ 6) P e value
34.0 (32.0e42.0) 35.0 (27.0e44.0) 0.836
2.0 (1.0e5.0) 2.0 (2.0e4.0) 1.000
2.0 (1.0e5.0) 1.5 (1.0e2.0) 0.461
2.0 (1.0e5.0) 1.5 (1.0e2.0) 0.511
6.0 (5.0e8.0) 5.5 (5.0e7.0) 0.605
25523.0 (3130.0e88502.8) 9195.0 (2271.0e14491.2) 0.026
16.0 (3.5e51.0) 10.0 (9.0e28.0) 0.143
100 (50e300) 150 (50e350) 0.195
4 (44.4%) 1 (16.6%) 0.287
5 (55.6%) 5 (83.4%) 0.580
3 (33.3%) 0 (0.0%) 0.229
3 (33.3%) 2 (33.3%) 1.000
Fig. 1. hCG values at the time of CSP diagnosis in 15 patients. B: Successful systemic
MTX treatment patients. C: Unsuccessful systemic MTX treatment patients. CSP, ce-
sarean scar pregnancy; MTX, methotrexate.
Fig. 2. GS size at the time of CSP diagnosis in 15 patients. B: Successful systemic MTX
treatment patients. C: Unsuccessful systemic MTX treatment patients. CSP, cesarean
scar pregnancy; MTX, methotrexate.
Fig. 3. hCG value and GS size at the time of CSP diagnosis in 15 patients. B: Successful
systemic MTX treatment patients. C: Unsuccessful systemic MTX treatment patients.
CSP, cesarean scar pregnancy; MTX, methotrexate.
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(P ¼ 0.089) (Fig. 2).
Among the five patients with hCG values less than 17757.0 mIU/
mL and GS sizes less than 10.4mm, four (80.0%) did not need UAE or
a laparotomy, and only one (20.0%) needed UAE or a laparotomy.
Among the seven patients with hCG values of 17757.0 mIU/mL or
higher and GS sizes 10.4 mm or larger, all patients needed UAE or a
laparotomy. Compared to the group with hCG values less than
17757.0 mIU/mL and GS sizes less than 10.4 mm, the number of
patients who needed UAE or a laparotomy was significantly greater
in the group with hCG values of 17757.0 mIU/mL or higher and/or
GS sizes of 10.4 mm or higher (P ¼ 0.010) (Fig. 3).
Discussion
The results of this study revealed that hCG values less than
17757.0 mIU/mL and GS sizes less than 10.4mm are indications that
MTX medical treatment is likely to successfully treat CSP patients.
There are cases in which UAE and/or TAH are required because
of extensive bleeding and uterine rupture during the treatment for
CSP. In a systematic review reported by Petersen et al. the success
rate of dilatation and curettage (D&C) for treating CSP patients was
48.1%, and serious complications occurred in 21.0% of patients. The
success rate of D&C or hysteroscopy after UAE has been reported as45695.4% and the serious complication rate reported as 1.2% [14]. The
hemostatic effects of UAE are very important for controlling
extensive bleeding, and UAE is considered to have therapeutic ef-
fects on CSP. However, a systematic review by Soro et al. reported
that UAE affected the occurrence of implantation and placenta
accrete [15]. Thus, UAE should not be used indiscriminately in CSP
patients who desire future pregnancies. As an alternative, MTX has
been used as one of the first treatment options for CSP patients.
In this study, the success rates of systemic MTX were 75.0% in
patients with hCG values less than 17757.0 mIU/mL, 80.0% in pa-
tients with GS sizes less than 10.4 mm, and 80.0% in patients with
both an hCG value less than 17757.0 mIU/mL and a GS size less than
10.4 mm. The success rates of these groups were equal to or higher
than the success rates for systemic MTX reported in the systematic
review reported by Petersen et al. [14]. In CSP patients with hCG
values less than 17757.0mIU/mL and CSP patients with GS sizes less
than 10.4 mm, systemic MTX should be the first treatment choice
for patients who wish to have future pregnancies. Additionally, the
success rate of systemic MTX was 0.0% in patients with hCG values
17757.0 mIU/mL or higher, 20.0% in patients with GS sizes of
10.4 mm or larger, and 0.0% in patients with both an hCG value of
17757.0 mIU/mL or higher and a GS size of 10.4 mm or larger. The
success rates in these groups were very low. It has been suggested
that systemic MTX should not be recommended for CSP patients
with hCG values of 17757.0 mIU/mL or higher and CSP patients with
a GS size of 10.4 mm or larger. Interventional therapies, such as
D&C or hysteroscopy after UAE, resection of a CSP through a
transvaginal approach, and a laparoscopy, should be recommended
instead [14].
This study was retrospective and used data from multiple
perinatal medical centers; however, only 15 cases were included in
this study. This presented a major limitation; thus, future pro-
spective studies are necessary to determine criteria and manage-
ment guidelines for MTX use in CSP.
In conclusion, when selecting systemic MTX as the first treat-
ment in CSP patients, those with an hCG value less than 17757.0
mIU/mL and a GS size less than 10.4 mm are likely to achieve
positive outcomes.Funding/support statement
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